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Introduction
As evolution occurred slowly through time, individual cells began
to assemble into multi-cellular colonies. The advantages awarded
to a community of cells are often greater than those for an individ-
ual. Survival and reproduction are part of the communal benefits.
Similarly, a parallel can be drawn to single cancer cell in the brain.
Its presence as a singular entity in the bustling metropolis of normal
neuronal cells may seem harmless and even insignificant at the be-
ginning. But once the cell 'plants its root', a community of cancerous
cells arises. The resulting brain tumour is inevitable, in addition,
neighbouring healthy cells undergo continuous cellular necrotic in-
sult through hypoxia and nutrient deprivation. Subtle clinical signs
and symptoms may begin to manifest as fewer functional neuronal
cells are present. Altered personality traits, chronic throbbing head-
aches and weakness in the extremities are the signs of a brain tumour.
However, such clinical features are ambiguous, especially in the early
stages of tumour formation and can be mistaken for other neurologi-
cal disorders. Delay in diagnosis can reduce a patient's median sur-
vival time as much as the lack of therapeutic treatment. The current
mainstay for brain tumour therapy is surgical resection and radia-
tion (to induce DNA damage and subsequent death of any remain-
ing tumour cells). This combination normally increases survival by
an additional 3-9 months. 1 Statistically, the patients will eventually
fall victim to the brain tumour. Magnetic resonance imaging (MRI)
scans have revealed that poor patient survival is predominantly due to
the rapid recurrence of tumour growth at the site of resection rather
than additional de novo tumour formation in other parts of the brain.2
This raises the question – How do cancer cells continue to prolifer-
ate rapidly despite the removal of an entire tumour (or nearly entire
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Genesis of new cells in the mammalian brain has previously been regarded as a negligible event; an assumption that long limited our under-
standing in the development of neoplasias. The recent discovery of perpetual lineages derived from neural stem cells has resulted in a new ap-
proach to studying the cellular behaviour of potential cancer stem cells in the brain. Glioblastoma multiforme (GBM), the most aggressive and
lethal brain tumour is derived from a group of cancerous stem cells known as glioma stem cells. GBM cells are impervious to conventional
therapies such as surgical resection and ionizing radiation because of their pluripotent and radioresistant properties. Thus in our study, we aim
to investigate whether a combination of chemo- and radio- therapies is an effective treatment for glioma stem cells. The study utilizes a specific
kinase inhibitor (ATMi) of the ATM (Ataxia-telangiectasia mutated) protein which is an essential protein in DNA-damage responses. In the pres-
ence of both low dose radiation and ATMi, glioma stem cells have rapid onset of cell death and reduction in growth. Since DNA damage can
be inherited through cell division, accumulated DNA breaks in later generations may also lead to cell death. The limitation of conventional ra-
diation therapy is that administration of fractionated (low) doses to reduce any potential harm to the surrounding healthy cells in the brain out-
weighs the benefits of high radiation doses to induce actual arrest in the propagation of malignant cells. Our study demonstrates a benefit in
using low dose radiation combined with chemotherapy resulting in a reduction in malignancy of glioma stem cells.
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tumour) combined with post-operative therapies that induce cell death
and should decrease the rate of tumour growth.
Shortcomings of conventional therapies
The reasons for brain tumour recurrence can be outlined in two
parts: Firstly, tumours are resistant to radiation therapy, thereby rap-
idly regaining population size. The progressive accumulation of mu-
tations and epigenetic silencing of key regulatory genes may be a
source of radiation-resistance within cancerous brain cells limiting
the effects of IR-induced DNA damage responses.3 Secondly, recent
advances have identified a small population of cancer stem cells
(CSCs) that has the ability to generate a large number of differen-
tiated progenies, while maintaining its pluripotent form.4 The fail-
ure of traditional therapy to remove CSCs can be attributed to the use
of typical cytotoxic drugs that often target the progeny of cancer
stem cells which have a higher proliferative index while sparing
tumourigenic stem cells with a lower proliferative rate. This demon-
strates that the limited understanding of the mechanisms involved in
brain tumour initiation, may have led to the unchanged median sur-
vival of patients for the past decades as the primary causes of the
tumour were unaffected by treatment. 5 Advances in diagnostic tools
in recent decades have markedly improved the resolution of computer
imaging (eg: MRI, radioisotope imaging, etc) which has lead to bet-
ter identification of brain tumour diseases. In the United States alone,
more than 13,000 deaths are related to brain tumours diseases with
~18,000 new cases being diagnosed annually.6 Brain tumour related
disease is also the second most common childhood cancer.7,8 The
principle hurdle in formulating an effective therapy may lie in target-
ing these brain tumour stem cells (BTSCs). As a model, we chose
the most malignant and common form of brain tumour; Glioblastoma
multiforme (GBM) to characterize the molecular properties of glioma
stem cells.
Glioblastoma multiforme stem cells
The World Health Organisation (WHO) classification of nervous
system tumours has been the gold standard for defining the malig-
nancy of brain tumours by employing a graded system (Table 1).9
Amongst the various tumours listed, grade IV gliomas or Glioblastoma
Multiforme (GBM) accounts for the majority of primary tumours
(~77%), and other known (~20%) intracranial tumours cases. Patients
that undergo surgical resection have an ~90% chance of recurrent
tumour formation. Survival statistics also reflect this with only 40%
of patients surviving for the first 6 months post-treatment and only
3.3% surviving after two years.2 Recent studies support a role of
BTSCs in the progression of GBM.10 This hypothesis postulates that
the recurrent tumour growth results from a rare subset of cells that
have the capacity to support development and progression of neo-
plasm. When neural- and glioma-extracted stem cells are compared,
only the latter has the capacity to initiate tumour growth when trans-
planted into an animal model.11,12 A further feature that supports post-
operative stem cell dependent tumour initiation is the determination
of the cellular origin of medulloblastoma in a mouse model. When
neural stem cells received a deletion in the Patched (Ptc) gene, ab-
normal stem cells begin to increase their proliferation rate within
the ventricular zone (VZ). Later, these Ptc deficient neural cells
can be observed migrating towards the cerebellum – the site where
medulloblastoma is initiated. 13 Although there is no clear mechanism
for the homing of 'medulloblastoma stem cells', this suggests that the
source of glioma stem cells may be different from the site of tumour
initiation.14 Potentially, glioma stem cells can also originate in a simi-
lar region to 'medulloblastoma stem cells' (eg: subgranular zone) where
asymmetrical cell division generates CSC progenies that migrate to
other regions and initiate tumour growth.14 If this hypothesis holds
true, then the elimination of glioma stem cells will have a general









< 40 years of age, common in
children and in young adults




< 45 years of age, more common
in young to middle-aged adults




< 45 years of age 2-3 years RB mut, CDK4/6 amp, PTEN loss,






> 45 years of age, frequent in fifth
decade of life but occassionally
occurs in the brain stem of children
6-12 months PTEN mut/OE, EGER amp/OE/mut,
MDM2 OE amp/OE, p53 mut, p16,
CyclicD1/3 amp/OE, RB mut,




Table 1. World Health Organisation (WHO) classification of brain tumours.
Different types of neuroepithelial origin tumours have been classified by WHO according to the cell types and genetic aberrations that predominate in the
tumour mass.9 GBM is the most aggressive form of brain tumour with the lowest survival rate. Abbreviations in table, (OE) Overexpressed, (amp) amplified,
(mut) mutated.
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The role of glioma stem cells in response to radia-
tion therapy
In response to radiation therapy, CSCs show increased prolifera-
tion and reduced cell death when compared to differentiated cells.
CSC survival may be due to an altered DNA damage response and
subsequent cell-cycle regulation. Supporting evidence exists from
Bao et al who observed that glioma stem cells have significantly in-
creased phosphorylation of Rad17, Chk1 and Chk2 proteins.15 The
latter proteins (Chk1 and Chk2) halt cell-cycle progression to facili-
tate DNA damage-response proteins relocating to the site of damage.
For instance, in the event of a G2/M arrest, sensor protein, Rad17 is
able to recruit the DNA-response complex (Rad1, Rad9 and Hus1)
to assist in the repair of DNA lesions.16 Although Rad1, Rad9 and
Hus1 proteins are functionally different and activation occurs in de-
fined sections of the cell-cycle, biochemical analysis demonstrates
that the activity of these proteins is mainly controlled by a member
of the PIKK (Phosphatidylinositol-3 kinase-like) family; the ATM
protein.16-18 The increased phosphorylation of these proteins in CSC
may be due to a lack of negative feedback loop to limit the response
to damaged DNA, or chronic activation of the initiator kinase (ATM).
Consequently, further investigation into the mechanism underlying
the dominant activation of signalling in glioma stem cells is re-
quired. ATM is essential for the DNA double strand break response
and its activation orchestrates several cellular processes such as regu-
lation of apoptosis, cell-cycle checkpoint activation and DNA repair.
Modulation of ATM activity may prove to be a starting point to de-
lineate the cause of radioresistance in glioma stem cells. In this study,
we focus on the role of ATM in the DNA damage response in GBM
and the potential use of ATM inhibitors to increase the GBM re-
sponse to low dose radiation.
Materials and methods
Established glioma stem cell and lymphoblastoid cell lines
Grade IV GBM neurosphere (NS) line – U-251 was a kind gift
provided by Dr Bryan Day. To generate neurospheres, U-251 cells
were maintained in NS-media containing NeuroCult® (StemCell
Technologies Inc), 20ng/ml recombinant human Epidermal Growth
Factor (R&D Systems), 10ng/ml recombinant human Fibroblast Growth
Factor (R&D Systems) and 1unit/ml of Heparin (Sigma). For passaging
to generate new neurospheres, cells were chemically dissociated
using trypsin and replated in a T-25 flask at a concentration of 1 x
105 cells per ml. A-T deficient human lymphoblastoid cell line
(AT1ABR) and normal human lymphoblastoid cell line (C3ABR)
were cultured as suspension cells in RPMI1640 medium supple-
mented with 6% v/v of fetal calf serum and penicillin/streptomycin.
Ionizing radiation exposure
All cultures were growth to 70%-80% confluency before being
subjected to radiation in a GammaCell40Exactor (Best Theratronics Ltd.)
with an exposure rate of 960cGy/min. Where indicated ATMi19 was
added to media 2hrs prior to irradiation. Treated cells were harvested
at indicated times and trypsinised (only U-251) before fixing with
1% of PFA for 15mins on ice and stored at -20°C with 70% ethanol
Cell proliferation
Growth of neurosphere U-251 cells was observed using a 40x ob-
jective microscope (Olympus Ckx41). Photographs of neurosphere cul-
tures with different treatments were taken at indicated time points using
an attached digital CCD colour camera (QImaging micropublisher
3.3). An average of 30 neurospheres was photographed from each
culture. Neurospheres that resembled clusters of cells rather than true
spheres were excluded from analysis. 20 Acquired photographs were
then analysed separately on a PC computer for size distribution of
spheres using Q-Capture Suite Software (QImaging).
Cell-cycle distribution
All cultures were collected at 16hrs, trypsinised (only U-251),
fixed and stored at -20°C as mentioned above. Cells were incubated
with Propidum iodide (50ug/ml) (Sigma) and RNAse A (Roche)
(100ug/ml) for 30mins before cell-cycle profiles were quantified
using a FACScanTM (BD Biosciences). Analysis was performed using
ModFit LTTM (BectonDickinson). Histograms are representative of
two independent experiments.
RESULTS
Establishing of glioma stem cells culture
The neurosphere culture is based on the fact that stem cells are
able to survive in the presence of mitogenic agents but the media
does not support the survival of differentiated cells. Tumour was ac-
quired from a GBM diagnosed patient (Figure 1a). Upon removal of
the tumour, extensive washes were conducted to remove any excess
haemoglobin. The tumour underwent mechanical dissociation to ex-
pose the tumour cells to subsequent trypsinization. A heterogeneous
population of cells released from the tumour were later separated
from tissue debris using a cell strainer. Collected cells were growth
in serum-free NS-media containing the appropriate mitogenic agents.
After 8-10 weeks of selective growth, only pure stem cells remained.
Proliferation of glioma stem cells after radiation
To date, studies regarding the use of ATM inhibitor to examine
radiosensitivity have relied heavily on the use of non-specific PIKK
inhibitors such as wortmannin and caffeine to understand the molecu-
lar mechanism of the DNA-damage response to radiation.21 Although
such an approach often displayed increase radiosensitivity, data ob-
tained from these studies could raise concern over its specificity as
other members of the PIKK family are also inhibited (eg: ATR,
DNA-PK, etc.).21,22 Thus, the use of non-specific PIKK inhibitors is
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ineffective in identifying novel therapeutic approaches as these stud-
ies only partially identified the IR-induced signalling pathways. This
lack of molecular tools is one of the reasons why the cause of
radioresistance of GBM has been difficult to elucidate.23 However, with
the identification of a specific kinase inhibitor of ATM (ATMi),19 we
can now study the molecular pathways involved in GBM radioresistance
in greater detail. In an initial experiment, we examined the growth
response of glioma stem cells in the presence of a therapeutically
relevant IR dose of 2Gy, followed by the comparison of ATMi in
combination with low dose radiation (2Gy) and high dose radiation
(10 Gy) alone.
When U-251 neurospheres were exposed to 2Gy of IR, growth was
40
Figure 1. ATMi exacerbates growth retardation of neurospheres in response to low dose IR.
Neurospheres were exposed to the indicated dose of IR. Where indicated cultures were treated with 5µM of ATMi for 2hr prior to IR treatment. a) Cultures
were photographed at the indicated time points after exposure to IR. The single cells suspension began to produce spheres after 24hrs in all cultures.
Differences in the size of spheroids formed between cultures could be identified from 48hrs. b) Average neurosphere sizes were determined by Q-Capture
Suite. Both untreated and 2Gy treated neurosphere cultures were capable of forming regular spheres whereas 10Gy and 2Gy with ATMi cultures had re-
duced spheroid formation. Columns show the average size and error bars represent the standard deviation of neurosphere diameter in each culture.
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similar to the untreated neurosphere culture during the first 24hrs.
However, a reduction in neurosphere size and number at 48hrs was
slightly more obvious in irradiated neurosphere cultures (Figure 1a).24
The reduction in growth may be due to activation of cell-cycle check-
points and damage repair pathways. By 96hrs, spheroids formed in
the irradiated (2Gy) neurosphere culture (~246um) and untreated
(~285um) were a similar size, demonstrating the survival of glioma
stem cells in response to low dose IR.
Further comparisons, indicated that neurosphere cultures that were
treated with ATMi prior to IR had a significant reduction in spheroid
formation. At 48hrs, 2Gy induced IR alone neurospheres had an
average diameter of >120µm in size whereas those treated with a
combination of ATMi and IR were smaller than ~75µm (Figure 1b).
Interestingly, the neurosphere culture that was treated with 10Gy of
IR exhibited a similar growth reduction to the culture given the com-
bination of 2Gy IR and ATMi, displaying an average diameter of
~80µm at 48hrs. By 96hrs, spheroid size in both cultures, 10Gy
(~173µm) and 2Gy with ATMi (~156µm) were ~1.7 fold smaller
than 2Gy IR alone-treated neurosphere cultures (~246µm). This data
strongly suggests that radiosensitivity could be induced in glioma
stem cells by inhibition of ATM kinase activity. In fact, inhibition of
ATM activity allowed a 2Gy dose to appear to be equivalently as le-
thal to GBM as a 10Gy dose. The data also indicated that ATM may
be required for radioresistance in neurospheres.
Effect of ATMi on the cell-cycle distribution of glioma stem cells
One of the hallmarks of A-T deficient cells is the extended delay
in G2 phase after irradiation.25 This delay relies on alternate (ATM-
independent) signalling pathways to arrest cells at the G2 cell-cycle
checkpoint.26 Corresponding with reduced neurosphere formation, we
attempted to delineate the cell-cycle distribution of glioma stem cells
in response to both ATMi and irradiation. Three asynchronous cell
types (AT1ABR; A-T deficient lymphoblastoid cell, C3ABR: control
lymphoblastoid cell and U-251: glioma neurosphere) were compared
following irradiation with or without ATMi pre-treatment. Cultures
were treated with 2Gy of IR before harvesting at 16hrs (Figure 2).19
When exposed to radiation, AT1ABR had a prominent shift to G2
(61.85%) accumulation as compared to G1 phase (13.69%). Conversely,
IR treatment of C3ABR cells and U-251 neurospheres resulted in
equal numbers of cells in G1 and G2 phase (Figure 2), suggesting
normal ATM activation which leads to the phosphorylation of Chk2.
However, the inclusion of ATMi prior to IR significantly increased
the accumulation of cells in G2 in both C3ABR and U-251 samples.
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Figure 2. Analysis of cell-cycle.
All cell types; AT1ABR (A-T deficient), C3ABR (normal) and U-251 (glioma) neurospheres were treated with or without 2Gy IR. Where indicated, cells
were treated with 5µM of ATMi for 2hr prior to IR treatment. Cells were harvested 16hrs post-irradiation and the cell cycle profile determined by propidium
iodide staining and flow cytometry.
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The increased in G2 accumulation was consistent with the data from
radiosensitive AT1ABR cells. ATMi specificity was confirmed by,
1) the lack of cell-cycle shift in cells that were not exposed to IR,
and 2) no change in G2 accumulation in AT1ABR (AT deficient)
cells when exposed to IR in the presence or absence of ATMi.
Discussion
To date, the lack of molecular tools for understanding the mecha-
nisms of GBM response to radiotherapy has prevented therapeutic
endeavours aimed at improving patient survival.15,23 In our study, the
use of a specific ATM kinase inhibitor provides data showing that
ATM activity may be crucial for the survival and radioresistance of
glioma stem cells. This is exemplified by the increase in G2 accumu-
lation in response to IR. Absence of ATM kinase activity prevents
rapid ATM-dependent phosphorylation of Chk2 therefore arrest of
cells at G2 phase requires alternate signalling via the ATR-Chk1 de-
pendent pathway.26,27 Response through this pathway occurs only at
later time points (5-24hrs), 28 once activated, ATR-Chk1 dependent
phosphorylation of CDC25 occurs. PCDC25 then interacts with 14-3-3
protein, translocating to the nucleus and preventing dephosphorylation
of CDC2, causing G2 cell-cycle arrest.26 Compensation for a lack of
ATM activation via increased ATR-dependent signalling could mani-
fest as an extended delay in G2 arrest observed in ATMi treated
cells. However, the advantage of employing ATM kinase inhibition
during IR induction is the lack of early arrest in G2 phase (1-4hr)
(Data not shown). 28 Glioma stem cells that have received damage
to their DNA in G2 phase can contribute significant chromosome
breakage/instability to its next generation of stem cells when they exit
the mitotic phase without any G2 arrest.29-31 However, damaged glioma
stem cells that are driven into the G1 phase may allow activation
of p53 pathway that can induce cells to undergo either cell death,
through the apoptosis pathway, or downstream phosphorylation of
p21 resulting in G1 accumulation. 32 In the latter process, DNA can
then be repaired by initiation of NHEJ (Non-homologous end join-
ing) prior to DNA synthesis. 26,33 Data obtained from the growth of
neurospheres in response to IR alone does suggest that glioma stem
cells may be inclined to rapid DNA-damage repair when ATM is
present. For example, a comparison of IR treated (2Gy) and untreated
neurosphere culture does not show any significant difference in sphe-
roid formation. The importance of ATM activity to glioma stem cell
survival is shown in (Figure 1b) where addition of ATMi to cells
treated with 2Gy IR could severely limit cell growth compared to
2Gy of IR alone.34
GBM radioresistance may be due to altered signalling pathways
that have been found during genomic studies of glioma tumours. Out
of 206 GBM extracted tumours, ~88% had an altered PI(3)K signalling
pathway, which could result in the dysregulation of the downstream
activation cascade including the p53, p16 and AKT pathways.35 ATM
can activate more than 900 different phosphorylation sites in 700
different proteins, a large proportion (48%) of which are related to
DNA replication, recombination and repair.36
To confirm these findings we plan to examine the effect of ATMi
pre-treatment in combination with low dose IR on DNA damage re-
sponsive signalling pathways, apoptosis, rate of DNA repair and cel-
lular proliferation.
In conclusion, data from the growth response of neurosphere cul-
ture treated with ATMi and low dose radiation showed significant
reduction in growth, and a delay in G2 cell-cycle arrest providing
us with preliminary results that suggest ATM-dependent signalling is
important in glioma stem cell survival. The removal of ATM kinase
activity and reduction of the resulting DNA damage and repair
signalling cascades had a significant impact on the radiation dose
response curve of glioma stem cells. In our studies, administration
of ATMi to cells treated with 2Gy IR resulted in cellular responses
similar to cells treated with 10Gy of IR. Therefore, inhibition of ATM
offers a potential platform for formulating effective therapeutic in-
terventions to be used in conjunction with current conventional ther-
apy.
Acknowledgements
We would like to express our deepest thanks and sincere gratitude
to our contributor, Dr David Walker from the BrizBrain & Spine re-
search foundation (Brisbane, Australia) for generous financial sup-
port in the above and ongoing study of glioma stem cell research.
References
1. Stieber VW, Mehta MP. Advances in Radiation Therapy for Brain Tumors Neurol
Clin 25: 1005-1033, 2007
2. Pennington C, Kilbr ide L, Grant R, Wardlaw JM. A pilot study of brain tumour
growth between radiotherapy planning and delivery. Clin Oncol 18: 104-108, 2006
3. Hambardzumyan D, Squar tro M, Holland EC. Radiation resistance and stem-like
cells in bra in tumors. Cancer Cell 10: 454-456, 2006
4. Reynolds BA, Weiss S. Clonal and population analyses demonstrate that an EGF-
responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol 175: 1-
13, 1992
5. Lu C, Shervington A. Chemoresistance in gliomas. Mol Cell Biochem 312: 1-2, 2008
6. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecu-
lar pathology of glioma. Nat Clin Prac t Neurol 2: 494-503, 2006
7. Nationa l cancer institute. http://www.cancer.gov/.
8. Miller R, Young J, Novakovic B. Childhood-Cancer. Cancer 75: 395-405, 1995
9. Kleihues P, Louis D, Scheithauer BW, et al. The WHO classifica tion of tumors of
the nervous system. J Neuropathol Exp Neurol 61: 215-225, 2002
10. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol
51: 1-28, 2004
11. Dirks PB. Brain tumour stem cells: the undercurrents of human brain cancer and
their rela tionship to neura l stem cells. Philos Trans R Soc Lond B Biol Sci 363:
139-152, 2008
12. Meissner KK, Kirkham DL, Doering LC. Transplants of neurosphere cell suspen-
sions from aged mice are functional in the mouse model of Parkinson's. Brain Res
1057: 105-112, 2005
13. Yang Z-J, Ellis T, Markant SL, et al. Medulloblastoma Can Be Initiated by Deletion
of Patched in Linea ge-Restricted Progenitors or Stem Cells. Cancr Cell 14: 135-145,
2008
14. Vescovi AL, Galli R , Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 6:
425-436, 2006
15. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by
preferential activation of the DNA damage response . Nature 444: 756-760, 2004
16. Bao S, Tibbetts RS, Brumbaugh KM, et al. ATR/ATM-mediated phosphorylation
of human Rad17 is required for genotoxic stress responses. Nature 411: 969-974,
2001
42
Yi Chieh Lim et al.: Combinatorial Effect of IR and ATMi on Glioma
17. Mitchell A. Cell cycle: From radiation to Rad17. Nat Rev Mol Cell Biol 2: 563,
2001
18. Muller F-J, Snyder EY, Loring JF. Gene therapy: can neural stem cells deliver?
Nat Rev Neurosci 7: 75-84, 2006
19. Hickson I, Zhao Y, Caroline, et al. Identifica tion and Characte riza tion of a Novel
and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM Cancer
Res 64: 9152-9159, 2004
20. Mori H, Ninomiya K, Kino-oka M, et al. Effect of neurosphere size on the growth
rate of human neural stem/progenitor cells. J Neurosci Res 84: 1682-1691, 2006
21. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition
of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin.
Cancer Res 58: 4375-4382, 1998
22. Zhou B-BS, Chaturvedi P, Spring K, et al. Caffeine Abolishes the Mammalian
G2/M DNA Damage Checkpoint by Inhibiting Ataxia-Telangiectasia-mutated Kinase
Activit. J Biol Chem 275: 10342-10348, 2000
23. Short SC, Martindale C, bourne S, Brand G, Woodcock M, Johnston P. DNA re-
pair afte r irradiation in glioma cells and normal human astocytes. Neuro-oncol 9:
404-411, 2007
24. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell
signalling and cancer. Nat Rev Mol Cell Biol 9: 759-769, 2008
25. Beamish H, Williams R, Chen P, Lavin MF. Defect in Multiple Cell Cycle
Checkpoints in Ataxia-Telangiectasia Postirradiation. J Biol Chem 271: 20486-
20493, 1996
26. Kastan MB, Lim D-s. The many substra tes and functions of ATM. Nat Rev Mol
Cell Biol 1: 179-186, 2000
27. Cuadrado M, Martinez-Pastor B, Fernandez-Capetillo O. ATR activation in re-
sponse to ioniz ing radiation: still ATM territory. Cell Div 1: 1-7, 2006
28. Stiff T, Cerosaletti K, Concannon P, O'Driscoll M, Jeggo PA. Replication inde-
pendent ATR signalling leads to G2/M arrest requiring Nbs1, 53BP1 and MDC1.
Hum Mol Genet 17: 3247-3253, 2008
29. Deckbar D, Birraux J, Krempler A, et al. Chromosome breakage after G2 check-
point re lease. J Cell Biol 176: 749-755, 2007
30. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics,
biology, and paths to treatment. Genes Dev 21: 2683-2710, 2007
31. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology
of a grave matter. Genes Dev 15: 1311-1333, 2001
32. Barlow C, Brown KD, Deng C-X, Tagle DA, Wynshaw-Boris A. Atm selectively
regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways.
Nat Genet 17: 453-456, 1997
33. Lisby M, Rothstein R. DNA damage checkpoint and repa ir centers. Curr Opin
Cell Biol 16: 328-334, 2004
34. Dimberg Y, Tottmar O, Aspberg A, Ebendal T, Johansson J, Walinder G. Effects
of Low-dose X-irradia tion on Mouse-brain Aggregation Cultures Int J Radiat Biol
61: 355-363, 1992
35. Chin L, Meyerson M, Aldape K, Bigner D, VandenBerg TM. Comprehensive genomic
characterization de fines human glioblastoma ge nes and cor e pathways. Nature 455:
1061-1068, 2008
36. Matsuoka S, Ballif BA, S mogorzewska A, et al. ATM and ATR Substrate Analysis
Reveals Extensive Protein Networks Responsive to DNA Damage. Science 316:
1160-1166, 2007
43
44
